Cefotaxime Injection 1g (Sodium Cefotaxime Hydrate)

Adult administration

Adults and children over 12 years of age should receive 1-2g (activity) of cefotaxime by intravenous or intramuscular injection once daily. In cases of severe disease or infections caused by moderately susceptible microorganisms, the dose can be increased to 4g (activity) per day.

Child administration

For newborns (within 14 days of birth), administer 20-50 mg (activity) per kg of body weight once daily, not exceeding 50 mg (activity) per kg of body weight. For infants and children (15 days to 12 years), dosage is based on body weight.

This drug must not be used in conjunction with solutions or drugs containing calcium. In particular, if this drug is mixed with calcium in neonates, it may precipitate and cause serious side effects; therefore, it must not be administered. Patients with allergies to this drug or who have had hypersensitivity reactions to cephalosporins or penicillin antibiotics should not use it. This drug may be risky for neonates or premature infants with bilirubin binding problems and should not be administered. Caution is advised for individuals with a history of drug allergies or those who may easily exhibit allergic symptoms such as bronchial asthma or rashes. In patients with poor kidney function, elderly patients, or those in poor general health, dosage adjustment or increased intervals may be necessary. This drug may cause side effects such as diarrhea, rash, liver dysfunction, and blood cell reduction, so if any unusual symptoms occur, immediate consultation with a physician is required. Rarely, serious allergic reactions, neurological disorders, hepatitis, or kidney impairment may occur, so the patient's condition should be monitored closely during administration. This drug can interact with other medications, so caution is needed, especially when used with diuretics, aminoglycoside antibiotics, and vitamin K antagonists. For pregnant or breastfeeding women, the safety of this drug has not been fully established; it should only be used when necessary and under a physician's discretion. In principle, it should not be administered to newborns or premature infants due to the risk of bilirubin encephalopathy. Caution should be exercised as side effects such as dizziness may occur during driving or operating machinery. When administering this drug, observe the injection site, and it is advisable to administer the intravenous injection slowly. The prepared solution should be used as soon as possible, and it should not be mixed with or administered simultaneously with calcium-containing solutions. While using this drug, it is important to regularly check liver, kidney, and blood parameters to verify any unusual conditions.

Serious side effects

Hives, severe swelling (edema), shock, chest tightness, difficulty breathing, cold sweat, pallor, high fever with severe rash, blisters, skin peeling, pain in oral/eye mucosa, difficulty breathing or shortness of breath, asthma attacks, respiratory difficulties with cough and fever, yellowing of the skin or eyes (jaundice), extreme lethargy, sudden and severe headache, lightning headache, seizures, confusion, visual disturbances, paralysis

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• increased liver enzymes
• headache
• dizziness
• bronchospasm
• loose stools

This drug should be stored in a tightly sealed container to prevent exposure to air or moisture, and it is best stored at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its effectiveness and safety.

Appearance

[For domestic use] Colorless, transparent vial filled with white to pale yellow crystalline powder [For export] Colorless, transparent vial filled with white to pale yellow crystalline powder

Package unit

Vial (1g) x10